← All trials
NCT04993690
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 6, 2021
- Primary completion
- Jul 30, 2023
- Completion date
- Dec 31, 2023
- First posted
- Aug 6, 2021
- Last posted
- Aug 10, 2021
- Enrollment
- 156
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangzhou Lupeng Pharmaceutical Company LTD.Lead sponsor
- Chinese Academy of Medical SciencesStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.